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OBJECTIVE: To generate estimates of the potential number
of patients with rheumatoid arthritis (RA), who are con-
sidered candidates for etanercept in the Dutch health care
setting in order to allow an assessment of the impact of
etanercept on the annual drug budget. METHODS: A lit-
erature search on incidence and prevalence data for RA
was performed on international and Dutch literature. A
subsequent expert panel was used to 1) reach consensus
on epidemiological data to be used for the budgetary im-
pact analysis in The Netherlands, 2) validate the findings
of the literature, 3) give estimates, where we did not find
reliable data in the literature. This panel was a represen-
tative sample of Dutch rheumatologists. The budgetary
impact analysis was performed from the perspective of
the Ministry of Health. RESULTS: The total number of
registered adult patients being treated by rheumatologists
was based on a Diagnosis-Registration System (range:
30,000–60,000). The panel estimated that 98% of the
patients will receive medication (range: 29,400–58,800) and
that 7% of those patients are candidates for etanercept
(range: 2,058–4,116). The total cost for etanercept is be-
tween NLG 64,084,000 (EURO 29,080,051) and NLG
128,169,000 (EURO 58,160,557), which is based on a
twice weekly injection of NLG 299.42 (EURO 135.87).
The expected costs are between NLG 49,265,000 (EURO
22,355,482) and NLG 98,530,000 (EURO 44,710,965),
when incorporating preliminary treatment termination
and switching to a once weekly dosage. CONCLUSION:
The use of literature and an expert panel allowed us to
make a budgetary impact analysis for etanercept, which
contributed to obtaining reimbursement.
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OBJECTIVES: To investigate the suitability of data sources
in Germany for methodologically sound and comprehen-
sive cost-of-illness studies and to demonstrate this by using
appropriate data sources to quantify the cost of illness
imposed by osteoporosis from the societal perspective.
METHODS: Secondary analysis of official and administra-
tive statistics, of structural data and of relevant publica-
tions was used to evaluate their appropriateness to estimate
direct and indirect cost incurred by osteoporosis and its se-
quelae. RESULTS: Suitable statistics are available in Ger-
many relating to the corresponding positions of the Inter-
national Classification of Diseases, 9th edition (ICD-9).
These statistics mostly cover resource use and days off
work, for example, rather than immediate costs, which can
be calculated using an adequate cost factor such as cost per
treatment day in hospital. In some cases, costs are given di-
rectly, as is the case with rehabilitation and long-term care
statistics, for example. The total annual direct and indirect
costs of osteoporosis and related fractures amounted to 4.3
billion DM in 1997. Direct costs for treatment of fractures
were corrected for non-osteoporotic causes; indirect costs
incurred by loss of productivity were discounted by 5% an-
nually. The largest part of 58% was caused by treatment in
acute hospitals and rehabilitation units. Further 15% of to-
tal costs were devoted to long-term nursing care and 13%
to outpatient care. Indirect costs due to inability to work,
early retirement and premature mortality amounted to
15% of total costs and were relatively low as compared to
other chronic diseases. CONCLUSIONS: (1) About three
quarter of the considerable costs imposed by osteoporosis
were devoted to late complications whereas cost for pre-
vention and rehabilitation were low. (2) Cost of illness can
be estimated in Germany for most of the diseases that are
classified on the 3-digit level of the ICD-9.
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Approximately 700,000 vertebral fractures occur annu-
ally in the US. However, vertebral fractures are perceived
as being inexpensive. Previous acute care cost estimates
range from approximately $2,300–$6,000. OBJECTIVE:
To estimate the acute care costs and resource intensity of
vertebral fractures in women. METHODS: The Nation-
wide Inpatient Sample (NIS) database was used to iden-
tify all admissions due to vertebral fracture (closed only,
without spinal injury: pathologic, cervical, thoracic, lum-
bar, unspecified; ICD-9 codes 733.13, 805.0x, 805.2x,
805.4x, 805.4x, 805.8x). Cases were excluded if charges
	$30,000. The NIS includes random samples of hospital
discharge abstracts across all payers from 22 states in the
US from 1997. Sampling weights were applied to create
national estimates. Charges, length-of-stay (LOS) and dis-
charge disposition were analyzed by age group. RE-
SULTS: In 1997, there were 57,807 hospital admissions
for vertebral fractures in women. Mean charges and LOS
were $8,082 and 5.7 days, respectively. Over one-third
were discharged to long-term care (LTC), another 29.4%
required other follow-up care. Patients aged 75 had
longer LOS and used more post-acute care compared to
younger patients. Overall, LOS and post-acute care for
vertebral fractures are slightly below that of hip fractures
(6.8 LOS, 49% LTC, 34% other follow-up care) and
higher versus all other types of fractures (4.9 LOS, 28%
LTC, 26% other care). CONCLUSIONS: This study sug-
gests that vertebral fractures are more expensive and re-
source intensive than previously reported. Furthermore,
